US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Vyome Holdings, Inc.

2.59

-0.0200-0.77%

Post-market: 2.690.1000+3.86%19:59 EST

Volume:124.93K

Turnover:330.28K

Market Cap:14.62M

PE:-0.01

High:2.76

Open:2.57

Low:2.56

Close:2.61

52wk High:305.00

52wk Low:1.75

Shares:5.64M

Float Shares:3.10M

Volume Ratio:0.55

T/O Rate:4.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-183.1419

EPS(LYR):-0.7646

ROE:--

ROA:-24.52%

PB:5.78

PE(LYR):-3.39

Loading ...

Overview Company News Filings

BRIEF-Vyome Files For VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over The Next 6 Months

Vyome Holdings Inc - FDA Interactions Planned in Q2 2026 for Phase 3 Protocol

THOMSON REUTERS

Vyome Holdings Inc - Orphan Drug Status Confers $3M Pdufa Fee Waiver

THOMSON REUTERS

Vyome Files for Vt-1953 Orphan Drug Status, Furthers Strategic Focus on Vt-1953 Program Over the Next 6 Months

THOMSON REUTERS

BRIEF-Vyome Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results

Vyome Successfully Capitalizes All Vt-1953 Funding Requirements for Initial Phase 3 Results

THOMSON REUTERS

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:58 AM

Independent Analyst Values Vyome’s Vt-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study

THOMSON REUTERS

Vyome Holdings Inc - Current Vt-1953 Valuation With Phase 2 Estimated at USD 455 Mln

THOMSON REUTERS

Vyome Holdings - on Dec 17, Entered Binding Loi With Livechain and Remus - SEC Filing

THOMSON REUTERS

Vyome Holdings Subsidiary to Acquire Humanyze Note from Remus in Stock Deal

LiveChain to Acquire Senior Secured Note in Humanyze

Vyome Subsidiary Livechain (Lich) to Acquire Senior Secured Note in Humanyze, an Mit Incubated Company

THOMSON REUTERS

BRIEF-Vyome Reports Positive Final Phase 2 Results For VT-1953 Plans To Advance Into Pivotal Study For FDA Approval

Vyome Holdings Inc - to Engage With FDA to Design and Initiate a Pivotal Phase Iii Clinical Study in 2026

THOMSON REUTERS

Vyome Reports Positive Final Phase 2 Results for Vt-1953; Plans to Advance Into Pivotal Study for FDA Approval

THOMSON REUTERS

Vyome Holdings Inc - Vt-1953 Was Well-Tolerated, With No New Safety Concerns Observed

THOMSON REUTERS

Vyome Reports Positive Phase 2 Results for VT-1953 in Malignant Fungating Wounds

BRIEF-Vyome Holdings Files Prospectus Related To Resale Of 610,185 Shares Of Common Stock By Selling Stockholders

Vyome Holdings Appoints Dr. Aditya Bardia as Senior Medical Advisor

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/HIND/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HIND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIND\",,,,,undefined,":{"symbol":"HIND","market":"US","secType":"STK","nameCN":"Vyome Holdings, Inc.","latestPrice":2.59,"timestamp":1771016400000,"preClose":2.61,"halted":0,"volume":124927,"hourTrading":{"tag":"盘后","latestPrice":2.69,"preClose":2.59,"latestTime":"19:59 EST","volume":2464,"amount":6532.76,"timestamp":1771030749255,"change":0.1,"changeRate":0.03861,"amplitude":0.053436},"delay":0,"changeRate":-0.007662835249042153,"floatShares":3099100,"shares":5644494,"eps":-183.1419,"marketStatus":"Closed","change":-0.02,"latestTime":"02-13 16:00:00 EST","open":2.57,"high":2.755,"low":2.56,"amount":330278.6670491,"amplitude":0.074713,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-183.1419,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":5,"adr":0,"listingDate":1475726400000,"exchange":"NASDAQ","adjPreClose":2.61,"preHourTrading":{"tag":"盘前","latestPrice":2.56,"preClose":2.61,"latestTime":"09:22 EST","volume":1495,"amount":3657.01817,"timestamp":1770992571890,"change":-0.05,"changeRate":-0.019157,"amplitude":0.066858},"postHourTrading":{"tag":"盘后","latestPrice":2.69,"preClose":2.59,"latestTime":"19:59 EST","volume":2464,"amount":6532.76,"timestamp":1771030749255,"change":0.1,"changeRate":0.03861,"amplitude":0.053436},"volumeRatio":0.550957},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIND\",,,,,undefined,":{"symbol":"HIND","floatShares":3099100,"roa":"-24.52%","roe":"--","lyrEps":-0.76459,"volumeRatio":0.550957,"shares":5644494,"dividePrice":0,"high":2.755,"amplitude":0.074713,"preClose":2.61,"low":2.56,"week52Low":1.75,"pbRate":"5.78","psRate":"42.42","week52High":305,"institutionHeld":0,"latestPrice":2.59,"eps":-183.1419,"divideRate":0,"volume":124927,"delay":0,"ttmEps":-183.1419,"open":2.57,"prevYearClose":3.44,"prevWeekClose":2.74,"prevMonthClose":1.92,"prevQuarterClose":3.44,"fiveDayClose":2.74,"twentyDayClose":3.09,"sixtyDayClose":4.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HIND\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-14","symbol":"HIND","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":-3.12},{"market":"US","date":"2025-08-15","symbol":"HIND","defaultRemindTime":1755264600000,"type":"split","dateTimestamp":1755230400000,"forFactor":4,"toFactor":1,"ratio":4},{"market":"US","date":"2025-08-14","symbol":"HIND","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-2.25},{"market":"US","date":"2025-05-21","symbol":"HIND","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747800000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2025-05-09","symbol":"HIND","defaultRemindTime":1746797400000,"type":"split","dateTimestamp":1746763200000,"forFactor":25,"toFactor":1,"ratio":25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HIND\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HIND\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1763528400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HIND\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HIND","date":"2026-02-12","current":-0.014524,"percent":0.866667,"low":-23.816091,"twenty":-20.473816,"median":-3.111295,"eighty":-1.761053,"high":-0.001601,"avg":-9.718152,"sd":8.896206,"marketCap":14449904},"quantilePoints":[{"date":"2025-08-22","current":-12.854344,"twenty":-12.392244,"median":-11.699095,"eighty":-11.005946,"marketCap":20748595},{"date":"2025-08-29","current":-11.259279,"twenty":-13.22027,"median":-12.854344,"eighty":-11.500884,"marketCap":18173952},{"date":"2025-09-05","current":-9.124707,"twenty":-13.182739,"median":-11.259279,"eighty":-10.03366,"marketCap":14728473},{"date":"2025-09-12","current":-0.001997,"twenty":-12.854344,"median":-10.288753,"eighty":-0.00213,"marketCap":2910},{"date":"2025-09-19","current":-0.001751,"twenty":-12.467306,"median":-9.124707,"eighty":-0.001933,"marketCap":2551},{"date":"2025-09-26","current":-20.664803,"twenty":-13.499407,"median":-10.288753,"eighty":-0.001997,"marketCap":30109879},{"date":"2025-10-03","current":-20.473816,"twenty":-20.473816,"median":-11.259279,"eighty":-0.002098,"marketCap":29831599},{"date":"2025-10-10","current":-21.00858,"twenty":-21.00858,"median":-13.018541,"eighty":-0.002106,"marketCap":30610783},{"date":"2025-10-17","current":-19.327894,"twenty":-20.855791,"median":-13.499407,"eighty":-0.00213,"marketCap":28161920},{"date":"2025-10-24","current":-20.850495,"twenty":-20.850495,"median":-19.346992,"eighty":-0.002143,"marketCap":30380443},{"date":"2025-10-31","current":-21.039016,"twenty":-20.850495,"median":-19.786263,"eighty":-9.124707,"marketCap":30655130},{"date":"2025-11-07","current":-21.340651,"twenty":-21.039016,"median":-20.206435,"eighty":-10.010203,"marketCap":31094630},{"date":"2025-11-14","current":-18.588235,"twenty":-21.00858,"median":-20.168237,"eighty":-10.03366,"marketCap":27084192},{"date":"2025-11-21","current":-17.984966,"twenty":-21.00858,"median":-20.037322,"eighty":-10.543846,"marketCap":26205192},{"date":"2025-11-28","current":-3.129419,"twenty":-20.886349,"median":-19.767164,"eighty":-7.929274,"marketCap":29238478},{"date":"2025-12-05","current":-3.075047,"twenty":-20.851554,"median":-19.327894,"eighty":-3.104045,"marketCap":28730474},{"date":"2025-12-12","current":-2.881724,"twenty":-20.850495,"median":-18.663643,"eighty":-3.026716,"marketCap":26924236},{"date":"2025-12-19","current":-2.342231,"twenty":-20.820331,"median":-18.362009,"eighty":-2.975968,"marketCap":21883703},{"date":"2025-12-26","current":-2.271547,"twenty":-20.790168,"median":-17.381696,"eighty":-2.665444,"marketCap":21223297},{"date":"2026-01-02","current":-2.078224,"twenty":-20.744922,"median":-13.229653,"eighty":-2.363376,"marketCap":19417059},{"date":"2026-01-09","current":-2.072183,"twenty":-20.685727,"median":-12.660825,"eighty":-2.260673,"marketCap":19360614},{"date":"2026-01-16","current":-1.866777,"twenty":-20.618426,"median":-10.790143,"eighty":-2.104806,"marketCap":17441486},{"date":"2026-01-23","current":-1.761053,"twenty":-20.541319,"median":-10.03366,"eighty":-2.062517,"marketCap":16453700},{"date":"2026-01-30","current":-1.292849,"twenty":-20.511156,"median":-6.2932,"eighty":-1.940481,"marketCap":12079217},{"date":"2026-02-06","current":-1.38951,"twenty":-20.503688,"median":-3.129419,"eighty":-1.87886,"marketCap":12982336},{"date":"2026-02-12","current":-1.546585,"twenty":-20.473816,"median":-3.111295,"eighty":-1.761053,"marketCap":14449904}],"updateTime":1771010721907},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HIND\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610342939","title":"BRIEF-Vyome Files For VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over The Next 6 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2610342939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610342939?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:04","pubTimestamp":1770811448,"startTime":"0","endTime":"0","summary":"BRIEF-Vyome Files For VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over The Next 6 MonthsFeb 11 (Reuters) - Vyome Holdings Inc HIND.O:VYOME FILES FOR VT-1953 ORPHAN DRUG STA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z70SD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","HIND","BK4007"],"gpt_icon":0},{"id":"2610934997","title":"Vyome Holdings Inc - FDA Interactions Planned in Q2 2026 for Phase 3 Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2610934997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610934997?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:03","pubTimestamp":1770811389,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z70SD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","HIND","BK4082"],"gpt_icon":0},{"id":"2610934990","title":"Vyome Holdings Inc - Orphan Drug Status Confers $3M Pdufa Fee Waiver","url":"https://stock-news.laohu8.com/highlight/detail?id=2610934990","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610934990?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:03","pubTimestamp":1770811389,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z70SD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4082","HIND"],"gpt_icon":0},{"id":"2610293499","title":"Vyome Files for Vt-1953 Orphan Drug Status, Furthers Strategic Focus on Vt-1953 Program Over the Next 6 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2610293499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610293499?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:03","pubTimestamp":1770811389,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z70SD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","HIND","BK4007"],"gpt_icon":0},{"id":"2608598869","title":"BRIEF-Vyome Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2608598869","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608598869?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:38","pubTimestamp":1770035923,"startTime":"0","endTime":"0","summary":"BRIEF-Vyome Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 ResultsFeb 2 (Reuters) - Vyome Holdings Inc HIND.O:VYOME SUCCESSFULLY CAPITALIZES ALL VT-1953 FUNDING REQUIREMENTS FOR INIT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nFWN3YY0XN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HIND","BK4082"],"gpt_icon":0},{"id":"2608865407","title":"Vyome Successfully Capitalizes All Vt-1953 Funding Requirements for Initial Phase 3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2608865407","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608865407?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:00","pubTimestamp":1770033615,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nFWN3YY0XN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HIND","BK4007","BK4082"],"gpt_icon":0},{"id":"2606373335","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:58 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2606373335","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606373335?lang=en_us&edition=fundamental","pubTime":"2026-01-27 22:58","pubTimestamp":1769525911,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:58 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nAQN2LJFQB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIND","BK4007","BK4082"],"gpt_icon":0},{"id":"2606849397","title":"Independent Analyst Values Vyome’s Vt-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2606849397","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606849397?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518827,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nFWN3YS07U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4082","HIND"],"gpt_icon":0},{"id":"2606841027","title":"Vyome Holdings Inc - Current Vt-1953 Valuation With Phase 2 Estimated at USD 455 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2606841027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606841027?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518827,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nFWN3YS07U:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HIND","BK4082","BK4007"],"gpt_icon":0},{"id":"2593433804","title":"Vyome Holdings - on Dec 17, Entered Binding Loi With Livechain and Remus - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2593433804","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593433804?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:12","pubTimestamp":1766524372,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT05C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4007","HIND"],"gpt_icon":0},{"id":"2593443383","title":"Vyome Holdings Subsidiary to Acquire Humanyze Note from Remus in Stock Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2593443383","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593443383?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:11","pubTimestamp":1766524295,"startTime":"0","endTime":"0","summary":"Vyome Holdings Inc. has entered into a binding letter of intent with LiveChain, Inc.  and Remus Capital Series B II, L.P.  for a proposed transaction in which LICH, an indirect subsidiary of Vyome Holdings, will acquire a senior secured convertible note issued by Sociometric Solutions, Inc., doing business as Humanyze, from Remus. As part of the agreement, LICH will issue shares representing 25% of its fully diluted common stock to Remus and will reserve an additional 10% for key and future employees. Following the transaction, current shareholders of LICH are expected to own 65% of the company. The agreement is subject to execution of definitive documents and customary closing conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL62nrY3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4007","LICH","HIND","BK4023"],"gpt_icon":0},{"id":"2593820480","title":"LiveChain to Acquire Senior Secured Note in Humanyze","url":"https://stock-news.laohu8.com/highlight/detail?id=2593820480","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593820480?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:03","pubTimestamp":1766408597,"startTime":"0","endTime":"0","summary":"Vyome Holdings Subsidiary LiveChain to Acquire Senior Secured Note in AI HR Analytics Firm Humanyze. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire  on December 22, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL5TRpGg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LICH","BK4082","BK4023","HIND","BK4007"],"gpt_icon":0},{"id":"2593487039","title":"Vyome Subsidiary Livechain (Lich) to Acquire Senior Secured Note in Humanyze, an Mit Incubated Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2593487039","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593487039?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:00","pubTimestamp":1766408403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA9WXQRF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4023","HIND","LICH","BK4007","BK4082"],"gpt_icon":0},{"id":"2589235325","title":"BRIEF-Vyome Reports Positive Final Phase 2 Results For VT-1953 Plans To Advance Into Pivotal Study For FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2589235325","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589235325?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:16","pubTimestamp":1765199818,"startTime":"0","endTime":"0","summary":"BRIEF-Vyome Reports Positive Final Phase 2 Results For VT-1953 Plans To Advance Into Pivotal Study For FDA ApprovalDec 8 (Reuters) - Vyome Holdings Inc HIND.O:VYOME REPORTS POSITIVE FINAL PHASE 2 RESU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE0XI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4007","HIND"],"gpt_icon":0},{"id":"2589531993","title":"Vyome Holdings Inc - to Engage With FDA to Design and Initiate a Pivotal Phase Iii Clinical Study in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2589531993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589531993?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:10","pubTimestamp":1765199427,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE0XI:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","HIND","BK4007"],"gpt_icon":0},{"id":"2589531323","title":"Vyome Reports Positive Final Phase 2 Results for Vt-1953; Plans to Advance Into Pivotal Study for FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2589531323","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589531323?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:10","pubTimestamp":1765199427,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE0XI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HIND","BK4007","BK4082"],"gpt_icon":0},{"id":"2589163353","title":"Vyome Holdings Inc - Vt-1953 Was Well-Tolerated, With No New Safety Concerns Observed","url":"https://stock-news.laohu8.com/highlight/detail?id=2589163353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589163353?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:10","pubTimestamp":1765199427,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE0XI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HIND","BK4082","BK4007"],"gpt_icon":0},{"id":"2589353559","title":"Vyome Reports Positive Phase 2 Results for VT-1953 in Malignant Fungating Wounds","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353559","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353559?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:02","pubTimestamp":1765198971,"startTime":"0","endTime":"0","summary":"Vyome Holdings Inc. has announced positive final results from a Phase 2 proof of concept study of VT-1953 topical gel in patients with malignant fungating wounds. VT-1953, described as a first-in-class immunomodulator for this indication, achieved both its primary and secondary endpoints in the study. The company plans to advance VT-1953 into a pivotal Phase III clinical trial, with the goal of seeking FDA approval. Vyome stated it remains well-capitalized through 2026 and aims to position VT-1953 as a potential treatment in a market estimated to reach $1 billion. The results of the Phase 2 study have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to genera","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL9Q15cc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HIND","BK4082"],"gpt_icon":0},{"id":"2586601502","title":"BRIEF-Vyome Holdings Files Prospectus Related To Resale Of 610,185 Shares Of Common Stock By Selling Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2586601502","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586601502?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:08","pubTimestamp":1764191336,"startTime":"0","endTime":"0","summary":"BRIEF-Vyome Holdings Files Prospectus Related To Resale Of 610,185 Shares Of Common Stock By Selling StockholdersNov 26  - Vyome Holdings Inc HIND.O:VYOME HOLDINGS INC - FILES PROSPECTUS RELATED TO RESALE OF 610,185 SHARES OF COMMON STOCK BY SELLING STOCKHOLDERSSource text: [ID:n0001213900-25-115481]Further company coverage: HIND.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X210T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIND","BK4007","BK4082"],"gpt_icon":0},{"id":"2586208094","title":"Vyome Holdings Appoints Dr. Aditya Bardia as Senior Medical Advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2586208094","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586208094?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:01","pubTimestamp":1764072062,"startTime":"0","endTime":"0","summary":"Vyome Holdings Inc. has appointed Dr. Aditya Bardia as Senior Medical Advisor to guide the clinical development of its lead asset, VT-1953, for the treatment of symptoms of malignant fungating wounds.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire  on November 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL4Smw0h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIND","BK4007","BK4082"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}]}}